Literature DB >> 23485092

Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization.

Krzysztof Lukaszuk1, Michał Kunicki, Joanna Liss, Mariusz Lukaszuk, Grzegorz Jakiel.   

Abstract

OBJECTIVE: To examine common clinical determinants, including patient age; levels of anti-Müllerian hormone (AMH), inhibin B, and follicle-stimulating hormone (FSH); antral follicle count (AFC); and number of oocytes retrieved, to predict live births in women undergoing in vitro fertilization. STUDY
DESIGN: Women undergoing cycles of intracytoplasmic sperm injection (ICSI) for the first time were reviewed retrospectively, and serum levels of AMH, inhibin B, and FSH, as well as AFC (days 1 and 4 of pre-ICSI menstrual period) and patient age were analyzed as determinants of live birth rates.
RESULTS: Of the patients studied, 35.71% (891/2495) became pregnant, with live births achieved in 32.20% (806/2495) of cycles initiated and in 46.37% (806/1738) of embryo transfers. Clinical pregnancy rate was 35.71% (891/2495) for cycles initiated and 51.26% (891/2318) for embryo transfers. Univariate analysis revealed that the odds of live birth significantly decreased with increasing age, declining AMH or inhibin B concentrations, and fewer oocytes retrieved. At AMH levels greater than 5.7 ng/ml, the odds of live birth were 3.18 times greater than for AMH levels less than 1.9 ng/ml [95% confidence interval (CI), 1.89-5.43]. Using multivariate logistic regression, only AMH (OR = 1.89; 95% CI, 1.00-3.60; p < 0.05) and AFC (OR = 1.86; 95% CI, 1.02-3.40; p < 0.05) showed statistically significant associations with live birth. Area under the curve for ROC (ROC(AUC)) indicated that AMH (AUC = 0.60) surpassed AFC (AUC = 0.59), number of oocytes retrieved (AUC = 0.59), inhibin B (AUC = 0.55), FSH (ROC(AUC) = 0.54) and chronological age (ROC(AUC) = 0.53) in predicting live birth.
CONCLUSIONS: In this assessment of various indices (i.e., age; levels of AMH, inhibin B, and FSH; AFC; and quantity of oocytes retrieved) for predicting live births for IVF patients, AMH, AFC and the quantity of oocytes retrieved constituted the most reliable determinants.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485092     DOI: 10.1016/j.ejogrb.2013.01.013

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  11 in total

1.  Serum antimüllerian hormone measurements with second generation assay at two distinct menstrual cycle phases for prediction of cycle cancellation, pregnancy and live birth after in vitro fertilization.

Authors:  Carolina P Rezende; Ana L Rocha; Cynthia Dela Cruz; Lavinia E Borges; Helen L Del Puerto; Fernando M Reis
Journal:  J Assist Reprod Genet       Date:  2014-07-12       Impact factor: 3.412

2.  Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study.

Authors:  Antonio La Marca; Valentina Grisendi; Simone Giulini; Giovanna Sighinolfi; Alessandra Tirelli; Cindy Argento; Claudia Re; Daniela Tagliasacchi; Tiziana Marsella; Sesh Kamal Sunkara
Journal:  J Assist Reprod Genet       Date:  2015-05-01       Impact factor: 3.412

Review 3.  Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Authors:  Ni-Jie Li; Qing-Yun Yao; Xiao-Qiong Yuan; Yong Huang; Yu-Feng Li
Journal:  Arch Gynecol Obstet       Date:  2022-07-30       Impact factor: 2.493

4.  Live birth following serial vitrification of embryos and PGD for fragile X syndrome in a patient with the premutation and decreased ovarian reserve.

Authors:  Dan Nayot; Jin Tae Chung; Weon-Young Son; Assangla Ao; Mark Hughes; Michael H Dahan
Journal:  J Assist Reprod Genet       Date:  2013-09-06       Impact factor: 3.412

5.  Relationships between the antral follicle count, steroidogenesis, and secretion of follicle-stimulating hormone and anti-Müllerian hormone during follicular growth in cattle.

Authors:  Kenichiro Sakaguchi; Yojiro Yanagawa; Koji Yoshioka; Tomoko Suda; Seiji Katagiri; Masashi Nagano
Journal:  Reprod Biol Endocrinol       Date:  2019-11-05       Impact factor: 5.211

6.  Decreasing quality of the new generations of anti-Müllerian hormone assays.

Authors:  Krzysztof Lukaszuk; Beata Ludwikowska; Joanna Liss; Michal Kunicki; Miroslaw Sawczak; Aron Lukaszuk; Lukasz Plociennik; Grzegorz Jakiel; Tomasz Wasniewski; Izabela Woclawek-Potocka; Dorota Bialobrzeska
Journal:  Biomed Res Int       Date:  2014-03-11       Impact factor: 3.411

Review 7.  Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.

Authors:  Philippe Lehert; Efstratios M Kolibianakis; Christos A Venetis; Joan Schertz; Helen Saunders; Pablo Arriagada; Samuel Copt; Basil Tarlatzis
Journal:  Reprod Biol Endocrinol       Date:  2014-02-20       Impact factor: 5.211

8.  Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH.

Authors:  Norbert Gleicher; Vitaly A Kushnir; Aritro Sen; Sarah K Darmon; Andrea Weghofer; Yan-Guang Wu; Qi Wang; Lin Zhang; David F Albertini; David H Barad
Journal:  J Transl Med       Date:  2016-06-10       Impact factor: 5.531

9.  Is the ovarian reserve influenced by vitamin D deficiency and the dress code in an infertile Iranian population?

Authors:  Soheila Arefi; Gholamreza Khalili; Homa Iranmanesh; Fattaneh Farifteh; Ahmad Hosseini; Human M Fatemi; Barbara Lawrenz
Journal:  J Ovarian Res       Date:  2018-07-24       Impact factor: 4.234

10.  Discordant anti-müllerian hormone (AMH) and follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth?

Authors:  Shunping Wang; Yi Zhang; Virginia Mensah; Warren J Huber; Yen-Tsung Huang; Ruben Alvero
Journal:  J Ovarian Res       Date:  2018-07-16       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.